Kurzfassung

A prospective multicenter phase 2 study of the chemotherapy-free combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in combination with Obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma and a high tumor burden